Challenges to addressing the unmet medical needs for immunotherapy targeting cold colorectal cancer

doi:10.4251/wjgo.v15.i2.215

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4096)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

172

WORD

HTML

1609

Figures (1-1)

335

Tables (1-3)

253

Sum=2413

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

219

Download

588

Sum=807

Publishing Process of This Article

Item

Count

Browse

218

Download

658

Sum=876

Feb 15, 2023 (publication date) through Feb 2, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastrointest Oncol. Feb 15, 2023; 15(2): 215-224
Published online Feb 15, 2023. doi: 10.4251/wjgo.v15.i2.215

Table 3 Ongoing clinical trials to improve response to immunotherapies targeting colorectal cancer

Strategy	NCT number	Intervention
Targeting tyrosine kinase	NCT04764006	Surufatinib (VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R inhibitor)
	NCT04819516	High-intensity focused ultrasound therapy; toripalimab (anti-PD-1 antibody)
	NCT04963283	Cabozantinib (anti-VEGFR2) plus nivolumab (anti-PD-1 antibody)
Targeting TGF-β	NCT03724851	TEW-7197 (TGF-β receptor ALK4/ALK5 inhibitor)
Targeting Wnt signaling	NCT02521844	ETC-159 (Porcupine inhibitor) plus Pembrolizumab (anti-PD-1 antibody)
Combination with chemotherapy	NCT04301557	Pembrolizumab plus binimetinib (MEK 1/2 inhibitor) plus FOLFOX plus irinotecan
	NCT04895137	FOLFOX6 plus bevacizumab (anti-VEGF A) plus anti-PD-1 antibody
	NCT03374254	Anti-PD-1 antibody plus oxaliplatin plus capecitabine plus radiotherapy then mesorectal excision
Cancer vaccine	NCT04046445	ATP128 (chimeric recombinant protein vaccine) plus BI754091 (IgG4Pro antibody inhibitor) plus VSV-GP128 (recombinant vesicular stomatitis virus)
	NCT04117087	KRAS peptide vaccine plus nivolumab (anti-PD-1 antibody) plus ipilimumab (anti-CTLA4 inhibitor)
	NCT04912765	Neoantigen dendritic cell vaccine plus nivolumab

VEGFR: Vascular endothelial growth factor receptor; FGFR1: Fibroblast growth factor receptor 1; CSF-1R: Colony stimulating factor 1 receptor; PD-1: Programmed cell death 1; TGF-β: Transforming growth factor beta; MEK 1/2: Mitogen-activated protein kinase 1/2; FOLFOX: Folinic acid, fluorouracil, and oxaliplatin; VEGF A: Vascular endothelial growth factor A; CTLA4: Cytotoxic T lymphocyte antigen-4.

Citation: Jeong KY. Challenges to addressing the unmet medical needs for immunotherapy targeting cold colorectal cancer. World J Gastrointest Oncol 2023; 15(2): 215-224
URL: https://www.wjgnet.com/1948-5204/full/v15/i2/215.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i2.215